| Identification | Back Directory | [Name]
[(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid mono(trifluoroacetate) | [CAS]
909725-62-8 | [Synonyms]
W146
(R)-3-AMino-(3-hexylphenylaMino)-4-oxobutylphosphonic acid (TFA salt)
(R)-3-AMINO-(3-HEXYLPHENYLAMINO)-4-OXOBUTYLPHOSPHONIC ACID (TFA SALT);W146
[(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid mono(trifluoroacetate) | [Molecular Formula]
C18H28F3N2O6P | [MDL Number]
MFCD21602904 | [MOL File]
909725-62-8.mol | [Molecular Weight]
456.394 |
| Hazard Information | Back Directory | [Uses]
W146 is a selective antagonists of spingosine-1-phosphate receptor subtype 1. | [Biological Activity]
W146 acts as an orthosteric antagonist. It is linked to blood lymphopenia and lung edema in mice. | [in vivo]
W146 (5 mg/kg, ip, prior to AMD3100 administration) pre-treatment shows approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony forming assays, compared to that in mice treated with AMD3100 alone[3]
The W146-mediated augmentation of KSL-HSPC mobilization is specific, because pretreatment of mice with W140 is unable to produce any effect on AMD3100-stimulated KSL-HSPC mobilization. Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count in mice[3]. | Animal Model: | Mice (4-6-week-old)[3]
. | | Dosage: | 5 mg/kg. | | Administration: | IP, 1 hour prior to AMD3100 (ADM) administration. | | Result: | Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration. |
| [storage]
Store at -20°C |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|